{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:20:13Z","timestamp":1791256813365,"version":"4.1.0"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background and objectives<\/jats:title>\n<jats:p>Some patients have insufficient treatment response to conventional disease-modifying antirheumatic drugs (cDMARD); although biologics have proven to be an effective treatment for RA, the effects that bDMARDs have on integumentary, cardiac, and immune systems and the high costs associated with these treatments, make that mesenchymal stem cell-based therapies (MSCs) for RA are being considered potential treatment methods. This work analyses the performance in safety and efficacy terms of MSCs techniques.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and finding<\/jats:title>\n<jats:p>A literature search was performed in PubMed, EMBASE, Cochrane Library, Web of Science, and Open Grey databases from inception to October 28, 2022. Three randomized controlled trials (RCTs) and one non-randomized controlled trial (non-RCTs), including 358 patients met our inclusion criteria and were included in qualitative synthesis; only RCTs were eligible for quantitative synthesis (meta-analysis). Meta-analysis of adverse events (AE) in RCTs showed no significant differences in the incidence of AE in the MSCs group compared to the control group (Risk ratio: 2.35; 95% CI, 0.58 to 9.58; I<jats:sup>2<\/jats:sup> = 58.80%). The pooled Risk ratio for non-serious and serious adverse events showed no statistical difference between intervention and control groups concerning the incidence of non-serious and serious adverse events (Risk ratio: 2.35; 95% CI, 0.58 to 9.51; I<jats:sup>2<\/jats:sup> = 58.62%) and (Risk ratio: 1.10; 95% CI, 0.15 to 7.97; I<jats:sup>2<\/jats:sup> = 0.0%) respectively. The Health Assessment Questionnaire (HAQ) and Disease Activity Score (DAS28) decreased in agreement with the decreasing values of C-reactive protein (CRP) and Erythrocyte sedimentation rate (ESR). Additionally, a trend toward clinical efficacy was observed; however, this improvement was not shown in the studies after 12 months of follow-up without continuous treatment administration.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This Systematic review and meta-analysis showed a favorable safety profile, without life-threatening events in subjects with RA, and a trend toward clinical efficacy that must be confirmed through high-quality RCTs, considerable sample size, and extended follow-up in subjects with RA.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0284828","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T17:34:19Z","timestamp":1690479259000},"page":"e0284828","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Safety and efficacy of mesenchymal stem cells therapy in the treatment of rheumatoid arthritis disease: A systematic review and meta-analysis of clinical trials"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3556-8977","authenticated-orcid":true,"given":"Luz Estella","family":"Mesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josue Guillermo","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"L\u00f3pez Quiceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0990-1679","authenticated-orcid":true,"given":"Freddy","family":"Barrios Arroyave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-0879","authenticated-orcid":true,"given":"Karolynn","family":"Halpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhyld C.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"5","key":"pone.0284828.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0095369","article-title":"A Systematic Critical Appraisal of Non-Pharmacological Management of Rheumatoid Arthritis with Appraisal of Guidelines for Research and Evaluation II.","volume":"9","author":"L Brosseau","year":"2014","journal-title":"PLoS One."},{"issue":"November 2018","key":"pone.0284828.ref002","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.biopha.2018.11.056","article-title":"Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran.","volume":"109","author":"M Ghoryani","year":"2019","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"pone.0284828.ref003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13287-022-02763-w","article-title":"Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I\/IIa, open-label, non-randomized pilot trial.","volume":"13","author":"R Vij","year":"2022","journal-title":"Stem Cell Res Ther."},{"issue":"10","key":"pone.0284828.ref004","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1136\/annrheumdis-2020-217798","article-title":"Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-\u03b3 treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis.","volume":"79","author":"X Xu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"pone.0284828.ref005","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.2147\/DDDT.S225613","article-title":"Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I\/II Study.","volume":"13","author":"L Wang","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"pone.0284828.ref006","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1541-4","article-title":"Serum IFN-\u03b3 levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis","author":"Y Yang","year":"2018","journal-title":"J Transl Med"},{"issue":"3","key":"pone.0284828.ref007","doi-asserted-by":"crossref","first-page":"e001694","DOI":"10.1136\/rmdopen-2021-001694","article-title":"All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015\u20132019.","volume":"7","author":"VK Bournia","year":"2021","journal-title":"RMD Open."},{"issue":"6","key":"pone.0284828.ref008","first-page":"334","article-title":"A meta-analysis of mortality in rheumatic diseases.","volume":"8","author":"E Toledano","year":"2012","journal-title":"Rheumatol Clin."},{"issue":"10","key":"pone.0284828.ref009","article-title":"The Global Prevalence of Rheumatoid Arthritis: A Meta-Analysis (Abstract).","volume":"72","author":"K Almutairi","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"SUPPL. 64","key":"pone.0284828.ref010","first-page":"21","article-title":"Autologous stem cell transplantation for rheumatoid arthritis\u2014interim report of 6 patients","volume":"64","author":"SJ Bingham","year":"2001","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"pone.0284828.ref011","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose-escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial.","volume":"76","author":"JM \u00c1lvaro-Gracia","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"pone.0284828.ref012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111592","article-title":"Mesenchymal stem cell-based therapy for rheumatoid arthritis.","volume":"22","author":"M Sarsenova","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"24","key":"pone.0284828.ref013","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1089\/scd.2013.0023","article-title":"Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy","volume":"22","author":"L Wang","year":"2013","journal-title":"Stem Cells Dev"},{"issue":"4","key":"pone.0284828.ref014","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcyt.2017.12.009","article-title":"Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1\/2 clinical trial.","volume":"20","author":"S Shadmanfar","year":"2018","journal-title":"Cytotherapy."},{"issue":"7818","key":"pone.0284828.ref015","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"JAC Sterne","year":"2011","journal-title":"BMJ"},{"issue":"192","key":"pone.0284828.ref016","article-title":"Mesenchymal stem\/stromal cells are a valuable source for treating immune-mediated disorders.","volume":"12","author":"A Markov","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"pone.0284828.ref017","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5487\/TR.2016.32.3.251","article-title":"Tumorigenicity Evaluation of Umbilical Cord Blood-derived Mesenchymal Stem Cells.","volume":"32","author":"SJ Park","year":"2016","journal-title":"Toxicol Res"},{"key":"pone.0284828.ref018","first-page":"610","article-title":"Tumour necrosis factor stimulates resorption and inhibits proteoglycan synthesis in cartilage","volume":"24","author":"J. Saklatvala","year":"1973","journal-title":"E & Maisin. NeurocYloL"},{"issue":"2","key":"pone.0284828.ref019","first-page":"295","article-title":"Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma.","volume":"71","author":"G Buchan","year":"1988","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"pone.0284828.ref020","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/eji.1830181122","article-title":"Excessive production of interleukin 6\/B cell stimulatory factor-2 in rheumatoid arthritis","volume":"18","author":"T Hirano","year":"1988","journal-title":"Eur J Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T17:34:56Z","timestamp":1690479296000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284828"}},"subtitle":[],"editor":[{"given":"Ryu","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0284828","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}